| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Alexander F Hoffman, Murat Oz, Tara Caulder, Carl R Lupic. Functional tolerance and blockade of long-term depression at synapses in the nucleus accumbens after chronic cannabinoid exposure. The Journal of neuroscience : the official journal of the Society for Neuroscience. vol 23. issue 12. 2003-08-05. PMID:12832502. |
these data demonstrate that long-term exposure to the active ingredient of marijuana blocks synaptic plasticity in the nac and reduces the sensitivity of gabaergic and glutamatergic synapses to both cannabinoids and opioids. |
2003-08-05 |
2023-08-12 |
rat |
| Tamas F Freund, Istvan Katona, Daniele Piomell. Role of endogenous cannabinoids in synaptic signaling. Physiological reviews. vol 83. issue 3. 2003-08-01. PMID:12843414. |
in addition, the behavioral effects of exogenous cannabinoids such as delta-9-tetrahydrocannabinol, the major active compound of hashish and marijuana, await explanation at the cellular and network levels. |
2003-08-01 |
2023-08-12 |
Not clear |
| Albert D Fraser, David Wort. Urinary excretion profiles of 11-nor-9-carboxy-Delta9-tetrahydrocannabinol: a Delta9-THC-COOH to creatinine ratio study #2. Forensic science international. vol 133. issue 1-2. 2003-07-29. PMID:12742686. |
the objective of the present study was to determine whether creatinine corrected urine specimens positive for cannabinoids could differentiate new marijuana use from the excretion of residual delta(9)-thc-cooh in chronic users of marijuana based on the huestis 0.5 ratio. |
2003-07-29 |
2023-08-12 |
human |
| Demetris P Papahatjis, Spyros P Nikas, Thanos Andreou, Alexandros Makriyanni. Novel 1',1'-chain substituted Delta(8)-tetrahydrocannabinols. Bioorganic & medicinal chemistry letters. vol 12. issue 24. 2003-07-16. PMID:12443781. |
1',1'-cyclopropyl side chain substituents enhance the affinities of delta(8)-tetrahydrocannabinol and respective cannabidiol analogues for the cb1 and cb2 cannabinoid receptors. |
2003-07-16 |
2023-08-12 |
Not clear |
| Allyn C Howlet. The cannabinoid receptors. Prostaglandins & other lipid mediators. vol 68-69. 2003-07-10. PMID:12432948. |
cannabinoid receptors were named because they have affinity for the agonist delta9-tetrahydrocannabinol (delta9-thc), a ligand found in organic extracts from cannabis sativa. |
2003-07-10 |
2023-08-12 |
Not clear |
| Giovanni Diana, Massimo Pieri, Giovanni Valentin. Effects of Win 55,212-2 on hippocampal CA1 long-term potentiation in experiments controlled for basal glutamatergic synaptic transmission. European journal of pharmacology. vol 453. issue 2-3. 2003-07-08. PMID:12398912. |
cannabinoids, the active components of marijuana, are presumed to affect memory by an action on long-term potentiation. |
2003-07-08 |
2023-08-12 |
Not clear |
| Declan Walsh, Kristine A Nelson, Fade Aziz Mahmou. Established and potential therapeutic applications of cannabinoids in oncology. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. vol 11. issue 3. 2003-06-12. PMID:12618922. |
cannabinoids are the active compounds extracted from cannabis. |
2003-06-12 |
2023-08-12 |
Not clear |
| Franjo Grotenherme. Pharmacokinetics and pharmacodynamics of cannabinoids. Clinical pharmacokinetics. vol 42. issue 4. 2003-06-11. PMID:12648025. |
however, its acid metabolite thc-cooh, the non-psychotropic cannabidiol (cbd), several cannabinoid analogues and newly discovered modulators of the endogenous cannabinoid system are also promising candidates for clinical research and therapeutic uses. |
2003-06-11 |
2023-08-12 |
Not clear |
| Franjo Grotenherme. Pharmacokinetics and pharmacodynamics of cannabinoids. Clinical pharmacokinetics. vol 42. issue 4. 2003-06-11. PMID:12648025. |
natural cannabis products and single cannabinoids are usually inhaled or taken orally; the rectal route, sublingual administration, transdermal delivery, eye drops and aerosols have only been used in a few studies and are of little relevance in practice today. |
2003-06-11 |
2023-08-12 |
Not clear |
| Maurizio Bifulco, Vincenzo Di Marz. [The endocannabinoid system as a target for the development of new drugs for cancer therapy]. Recenti progressi in medicina. vol 94. issue 5. 2003-06-09. PMID:12723496. |
studies on the main bioactive components of cannabis sativa, the cannabinoids, and particularly delta 9-tetrahydrocannabinol (thc), led to the discovery of a new endogenous signalling system that controls several physiological and pathological conditions: the endocannabinoid system. |
2003-06-09 |
2023-08-12 |
Not clear |
| Roger G Pertwee, Ruth A Ross, Susan J Craib, Adèle Thoma. (-)-Cannabidiol antagonizes cannabinoid receptor agonists and noradrenaline in the mouse vas deferens. European journal of pharmacology. vol 456. issue 1-3. 2003-05-19. PMID:12450575. |
we have found that cannabidiol can also interact with cannabinoid cb(1) receptor agonists in the mouse vas deferens, a tissue in which prejunctional cannabinoid cb(1) receptors mediate inhibition of electrically evoked contractions by suppressing noradrenaline and/or atp release. |
2003-05-19 |
2023-08-12 |
mouse |
| Roger G Pertwee, Ruth A Ross, Susan J Craib, Adèle Thoma. (-)-Cannabidiol antagonizes cannabinoid receptor agonists and noradrenaline in the mouse vas deferens. European journal of pharmacology. vol 456. issue 1-3. 2003-05-19. PMID:12450575. |
we conclude that cannabidiol antagonizes r-(+)-win55212 and cp55940 by acting at prejunctional sites that are unlikely to be cannabinoid cb(1) or cb(2) receptors. |
2003-05-19 |
2023-08-12 |
mouse |
| László Offertáler, Fong-Ming Mo, Sándor Bátkai, Jie Liu, Malcolm Begg, Raj K Razdan, Billy R Martin, Richard D Bukoski, George Kuno. Selective ligands and cellular effectors of a G protein-coupled endothelial cannabinoid receptor. Molecular pharmacology. vol 63. issue 3. 2003-05-12. PMID:12606780. |
the cannabinoid analog abnormal cannabidiol [abn-cbd; (-)-4-(3-3,4-trans-p-menthadien-[1,8]-yl)-olivetol] does not bind to cb(1) or cb(2) receptors, yet it acts as a full agonist in relaxing rat isolated mesenteric artery segments. |
2003-05-12 |
2023-08-12 |
mouse |
| Albert D Fraser, David Wort. Monitoring urinary excretion of cannabinoids by fluorescence-polarization immunoassay: a cannabinoid-to-creatinine ratio study. Therapeutic drug monitoring. vol 24. issue 6. 2003-05-07. PMID:12451292. |
huestis reported that serial monitoring of the major urinary cannabinoid metabolite (delta9-thc-cooh)-to-creatinine ratios in paired urine specimens (collected at least 24 hours apart) could differentiate new marijuana or hashish use from residual cannabinoid metabolite excretion in urine after previous drug use. |
2003-05-07 |
2023-08-12 |
human |
| Albert D Fraser, David Wort. Monitoring urinary excretion of cannabinoids by fluorescence-polarization immunoassay: a cannabinoid-to-creatinine ratio study. Therapeutic drug monitoring. vol 24. issue 6. 2003-05-07. PMID:12451292. |
the objective of this study was to determine whether a semiquantitative cannabinoids immunoassay (corrected for creatinine concentration) could differentiate new marijuana use from residual cannabinoid excretion in chronic users of marijuana or hashish compared with gc-ms. |
2003-05-07 |
2023-08-12 |
human |
| Albert D Fraser, David Wort. Monitoring urinary excretion of cannabinoids by fluorescence-polarization immunoassay: a cannabinoid-to-creatinine ratio study. Therapeutic drug monitoring. vol 24. issue 6. 2003-05-07. PMID:12451292. |
the authors conclude that fpia cannabinoid analysis should be further evaluated as an alternative to gc-ms quantitation to help distinguish new marijuana use from residual marijuana metabolite excretion in clinical drug treatment programs. |
2003-05-07 |
2023-08-12 |
human |
| Angelika Richter, Wolfgang Lösche. Effects of pharmacological manipulations of cannabinoid receptors on severity of dystonia in a genetic model of paroxysmal dyskinesia. European journal of pharmacology. vol 454. issue 2-3. 2003-05-06. PMID:12421641. |
was confirmed, cannabidiol (which has low affinity to cannabinoid receptors) tended to delay the progression of dystonia only at a high dose (150 mg/kg i.p.). |
2003-05-06 |
2023-08-12 |
Not clear |
| Paul Lecha. [Does cannabis have a therapeutic value?]. Bulletin de l'Academie nationale de medecine. vol 186. issue 2. 2003-04-29. PMID:12145840. |
researches on endogenous cannabinoids as well as on cannabinoids receptors agonists and antagonists may lead to discover new useful drugs devoid of the central nervous system unwanted effects of cannabis. |
2003-04-29 |
2023-08-12 |
Not clear |
| Carl L Hart, Amie S Ward, Margaret Haney, Sandra D Comer, Richard W Foltin, Marian W Fischma. Comparison of smoked marijuana and oral Delta(9)-tetrahydrocannabinol in humans. Psychopharmacology. vol 164. issue 4. 2003-04-23. PMID:12457271. |
although smoked marijuana contains at least 60 cannabinoids, delta(9)-tetrahydrocannabinol (delta(9)-thc) is presumed to be the cannabinoid primarily responsible for many marijuana-related effects, including increased food intake and subjective effects. |
2003-04-23 |
2023-08-12 |
Not clear |
| D Cota, G Marsicano, B Lutz, V Vicennati, G K Stalla, R Pasquali, U Pagott. Endogenous cannabinoid system as a modulator of food intake. International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity. vol 27. issue 3. 2003-04-17. PMID:12629555. |
despite the public concern related to the abuse of marijuana and its derivatives, scientific studies have pointed to the therapeutic potentials of cannabinoid compounds and have highlighted their ability to stimulate appetite, especially for sweet and palatable food. |
2003-04-17 |
2023-08-12 |
human |